Evidence map›Paper›PMID 34747265›Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2022

A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing.

Aasthaa Bansal, Patrick J Heagerty, Lurdes Y T Inoue, David L Veenstra, Charles J Wolock, Anirban Basu

Abstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aasthaa BansalThe Comparative Health Outcomes, Policy, and Economics Institute, School of Pharmacy, University of Washington, Seattle WA, USA.ORCID 0000-0001-5507-2640
Patrick J HeagertyDepartment of Biostatistics, University of Washington, Seattle WA, USA.
Lurdes Y T InoueDepartment of Biostatistics, University of Washington, Seattle WA, USA.
David L VeenstraThe Comparative Health Outcomes, Policy, and Economics Institute, School of Pharmacy, University of Washington, Seattle WA, USA.
Charles J WolockDepartment of Biostatistics, University of Washington, Seattle WA, USA.
Anirban BasuThe Comparative Health Outcomes, Policy, and Economics Institute, School of Pharmacy, University of Washington, Seattle WA, USA.ORCID 0000-0003-4238-7402

Funding

Personalized Risk-AdaptIve Surveillance strategies in cancEr -- PRAISER37CA218413 · NCI · UNIVERSITY OF WASHINGTON · PI BANSAL, AASTHAA · 2018 to 2024
$3.0M
NCI NIH HHS R37 CA218413
6 · The paper itself

Abstract

backgroundPatient surveillance using repeated biomarker measurements presents an opportunity to detect and treat disease progression early. Frequent surveillance testing using biomarkers is recommended and routinely conducted in several diseases, including cancer and diabetes. However, frequent testing involves tradeoffs. Although surveillance tests provide information about current disease status, the complications and costs of frequent tests may not be justified for patients who are at low risk of progression. Predictions based on patients' earlier biomarker values may be used to inform decision making; however, predictions are uncertain, leading to decision uncertainty.

methodsWe propose the Personalized Risk-Adaptive Surveillance (PRAISE) framework, a novel method for embedding predictions into a value-of-information (VOI) framework to account for the cost of uncertainty over time and determine the time point at which collection of biomarker data would be most valuable. The proposed sequential decision-making framework is innovative in that it leverages the patient's longitudinal history, considers individual benefits and harms, and allows for dynamic tailoring of surveillance intervals by considering the uncertainty in current information and estimating the probability that new information may change treatment decisions, as well as the impact of this change on patient outcomes.

resultsWhen applied to data from cystic fibrosis patients, PRAISE lowers costs by allowing some patients to skip a visit, compared to an "always test" strategy. It does so without compromising expected survival, by recommending less frequent testing among those who are unlikely to be treated at the skipped time point.

conclusionsA VOI-based approach to patient monitoring is feasible and could be applied to several diseases to develop more cost-effective and personalized strategies for ongoing patient care. HIGHLIGHTS: In many patient-monitoring settings, the complications and costs of frequent tests are not justified for patients who are at low risk of disease progression. Predictions based on patient history may be used to individualize the timing of patient visits based on evolving risk.We propose Personalized Risk-Adaptive Surveillance (PRAISE), a novel method for personalizing the timing of surveillance testing, where prediction modeling projects the disease trajectory and a value-of-information (VOI)-based pragmatic decision-theoretic framework quantifies patient- and time-specific benefit-harm tradeoffs.A VOI-based approach to patient monitoring could be applied to several diseases to develop more personalized and cost-effective strategies for ongoing patient care.

Indexed as

NeoplasmsBiomarkersCost-Benefit AnalysisDisease ProgressionHumansUncertaintyBiomarkersdynamic decision makingdynamic predictionpersonalized medicinevalue of information

Identifiers

PMID34747265
PMCPMC9007840

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.